Clinical Trials Register

Summary
EudraCT Number:	2018-004159-19
Sponsor's Protocol Code Number:	2018-00938
National Competent Authority:	Netherlands - Competent Authority
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2019-10-15
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Netherlands - Competent Authority

A.2

EudraCT number

2018-004159-19

A.3

Full title of the trial

Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study

Gebruik van de Copeptine meting na Arginine infusie voor de diagnose van diabetes insipidus – de CARGOx-studie

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study

Gebruik van de Copeptine meting na Arginine infusie voor de diagnose van diabetes insipidus – de CARGOx-studie

A.3.2

Name or abbreviated title of the trial where available

CARGOx

A.4.1

Sponsor's protocol code number

2018-00938

A.5.4

Other Identifiers

Name:

clinicaltrials.gov

Number:

NCT03572166

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	University Hospital Basel
B.1.3.4	Country	Switzerland
B.3.1 and B.3.2	Status of the sponsor	Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Swiss National Science Foundation
B.4.2	Country	Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	University Hospital Basel
B.5.2	Functional name of contact point	Julie Refardt
B.5.3	Address:
B.5.3.1	Street Address	Dr. Molewaterplein 40
B.5.3.2	Town/ city	Rotterdam
B.5.3.3	Post code	3015 GD
B.5.3.4	Country	Netherlands
B.5.4	Telephone number	+4161268 68 14
B.5.6	E-mail	j.refardt@erasmusmc.nl

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	L-Arginin-Hydrochlorid 21 % Braun
D.2.1.1.2	Name of the Marketing Authorisation holder	B. Braun Melsungen AG
D.2.1.2	Country which granted the Marketing Authorisation	Germany
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	L-Arginin-Hydrochlorid 21 % Braun
D.3.2	Product code	3899.99.99
D.3.4	Pharmaceutical form	Infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Parenteral use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Argininhydrochlorid
D.3.9.1	CAS number	1119-34-2
D.3.9.3	Other descriptive name	ARGININE HYDROCHLORIDE
D.3.9.4	EV Substance Code	SUB00579MIG
D.3.10	Strength
D.3.10.1	Concentration unit	g/l gram(s)/litre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	210.7
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Sodium Chloride 3% injection solution Baxter Healthcare Corporation
D.2.1.1.2	Name of the Marketing Authorisation holder	Baxter healthcare Corporation
D.2.1.2	Country which granted the Marketing Authorisation	United States
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Sodium Chloride 3% injection solution
D.3.2	Product code	2B1353
D.3.4	Pharmaceutical form	Infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Parenteral use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Natriumchlorid
D.3.9.3	Other descriptive name	SODIUM CHLORIDE
D.3.9.4	EV Substance Code	SUB12581MIG
D.3.10	Strength
D.3.10.1	Concentration unit	% percent
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	20
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP).

polyurie-polydipsie syndroom

E.1.1.1

Medical condition in easily understood language

The polyuria-polydipsia-syndrome includes central diabetes insipidus, a dysfunction of the pituitary gland and primary polydipsia, which is usually the result of a learned drinking behavior.

De polyurie-polydipsie-syndroom omvat de ziekten centrale diabetes insipidus, een aandoening van de hypofyseklier, of de primaire polydipsie, een ziekte die het resultaat is toegenomen vochtinname.

E.1.1.2

Therapeutic area

Diseases [C] - Hormonal diseases [C19]

MedDRA Classification

E.1.3

Condition being studied is a rare disease

Yes

E.2 Objective of the trial

E.2.1

Main objective of the trial

The aim of the study is to find a new, safe and easy-to-use diagnostic test for the diagnostic distinction between central diabetes insipidus and primary polydipsia. For that reason we compare the diagnostic accuracy of copeptin measurement after stimulation with arginine infusion to the current best diagnostic test copeptin measurement after hypertonic saline infusion.

Het doel van het onderzoek is het vinden van een nieuwe, veilige en gemakkelijk te gebruiken diagnostische test voor het diagnostische onderscheid tussen centrale diabetes insipidus en primaire polydipsie. Om die reden vergelijken we de diagnostische nauwkeurigheid van copeptinemeting na stimulatie met arginine-infusie met de huidige beste diagnostische test copeptine-meting na hypertonische zoutinfusie.

E.2.2

Secondary objectives of the trial

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Age ≥ 18 years  
2. Hypotonic polyuria / polydipsia syndrome defined as:
- polyuria >50ml/kg body weight/24h and polydipsia >3l /24h or known diabetes insipidus under treatment with DDAVP
- Urine-Osmolality <800mOsm/L

1. Leeftijd ≥ 18 jaar
2. Hypotonisch polyurie / polydipsie syndroom gedefinieerd als:
- polyurie> 50 ml / kg lichaamsgewicht / 24 uur en polydipsie> 3 l / 24 uur of bekende diabetes insipidus onder behandeling met DDAVP
- Urine-osmolaliteit <800 mOsm / L

E.4

Principal exclusion criteria

1. Polyuria / polydipsia secondary to diabetes mellitus, hypercalcemia or hypokalemia
2. Nephrogenic diabetes insipidus (defined as baseline copeptin level >21.4pmol/L)
3. Evidence of any acute illness
4. Epilepsy requiring treatment
5. Uncontrolled arterial hypertension (blood pressure >160/100mmHg at baseline)
6. Cardiac failure (NYHA III-IV)
7. Liver cirrhosis (Child B-C)
8. Uncorrected adrenal or thyroidal deficiency
9. Patients refusing or unable to give written informed consent
10. Pregnancy or breast feeding
11. End of life care

1. Polyurie / polydipsie secundair aan diabetes mellitus, hypercalciëmie of hypokaliëmie
2. Nefrogene diabetes insipidus (gedefinieerd als baseline copeptine-gehalte > 21.4pmol / L)
3. Bewijs van een acute ziekte
4. Epilepsie die behandeling vereist
5. Ongecontroleerde arteriële hypertensie (bloeddruk> 160/100 mmHg bij aanvang)
6. Hartfalen (NYHA III-IV)
7. Levercirrose (CHILD B-C)
8. Niet-gecorrigeerde bijnier- of schildkliertekort
9. Patiënten die weigeren of niet in staat zijn schriftelijke geïnformeerde toestemming te geven
10. Zwangerschap of borstvoeding
11. Einde levensduur zorg

E.5 End points

E.5.1

Primary end point(s)

The primary outcome is the overall diagnostic accuracy – defined as the proportion of correct diagnoses – of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia. Copeptin measurement after arginine-stimulation will be compared for non-inferiority to the current best diagnostic test copeptin measurement after hypertonic saline infusion.

Het primaire resultaat is de algehele diagnostische nauwkeurigheid - gedefinieerd als het aandeel van de juiste diagnoses - van elke diagnostische procedure bij het onderscheiden van patiënten met centrale diabetes insipidus van patiënten met primaire polydipsie. Copeptine-meting na argininestimulatie zal worden vergeleken voor niet-inferioriteit met de huidige beste diagnostische test copeptine-meting na hypertonische zoutoplossinginfusie.

E.5.1.1

Timepoint(s) of evaluation of this end point

At the end of the study

aan het einde van de studie

E.5.2

Secondary end point(s)

1. Estimation of sensitivity, specificity, and positive- and negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial or complete central diabetes insipidus) according to recommended diagnostic test criteria and a priori defined cut-off value.
2. best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial or complete central diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation
3. Accuracy, sensitivity and specificity of the copeptin cut-offs for both tests.
4. Frequency and severity of thirst, headache, nausea, vertigo and general malaise, assessed by visual analogue scale (VAS) during the tests
5. subjective burden assessed by visual analogue scale (VAS) during the tests
6. frequency of test preference according to evaluation at follow up visit
7. Health care costs of both tests

1. Schatting van gevoeligheid, specificiteit en positief- en negatief voorspellende waarde van beide diagnostische procedures voor elke diagnose (primaire polydipsie, gedeeltelijke of volledige centrale diabetes insipidus) volgens aanbevolen diagnostische testcriteria en een vooraf gedefinieerde grenswaarde.
2. best passende diagnostische copeptine-cut-off-waarden voor differentiatie tussen elke diagnose (primaire polydipsie, gedeeltelijke of volledige centrale diabetes insipidus) bij argininestimulatie en hypertonische zoutinfusiestimulatie
3. Nauwkeurigheid, gevoeligheid en specificiteit van de copeptine-resultaat voor beide tests.
4. Frequentie en ernst van dorst, hoofdpijn, misselijkheid, duizeligheid en algemene malaise, beoordeeld door visuele analoge schaal (VAS) tijdens de tests
5. subjectieve belasting beoordeeld door visuele analoge schaal tijdens de tests
6. frequentie van testvoorkeur volgens evaluatie bij vervolgbezoek
7. Gezondheidszorgkosten van beide tests

E.5.2.1

Timepoint(s) of evaluation of this end point

At the end of the study

aan het einde van de studie

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

Yes

E.6.2

Prophylaxis

E.6.3

Therapy

E.6.4

Safety

E.6.5

Efficacy

E.6.6

Pharmacokinetic

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

Yes

E.8.1.3

Single blind

E.8.1.4

Double blind

E.8.1.5

Parallel group

E.8.1.6

Cross over

Yes

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

Yes

E.8.2.2

Placebo

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

Yes

E.8.4

The trial involves multiple sites in the Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Germany

Italy

Switzerland

United Kingdom

E.8.7

Trial has a data monitoring committee

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

122

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

110

F.4.2.2

In the whole clinical trial

152

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

Follow-up visit 3 months after diagnostics are completed.

Vervolgbezoek 3 maanden nadat de diagnostiek is voltooid.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2019-10-15

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2019-12-16

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials